Interaction Between <i>PPARA</i> Genotype and β-Blocker Treatment Influences Clinical Outcomes Following Acute Coronary Syndromes
Sharon Cresci(Washington University in St. Louis), John A. Spertus(Saint Luke's Health System), Michael A. Province, Howard L. McLeod(Unknown), Sharon Marsh(Washington University in St. Louis), Carmen C. Sucharov(University of Colorado Denver), Daniel P. Kelly(Cardiovascular Institute of the South), David E. Lanfear(Henry Ford Health System), Carla J. Weinheimer(University of Washington), Philip G. Jones(University of Missouri–Kansas City), Adam Garsa(Washington University in St. Louis), Michael Courtois(Washington University in St. Louis), Jun Wu(Shanghai Jiao Tong University)
Cited by 19
Related Papers
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
|Circulation|2011|1.8k
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation
|Cell Metabolism|2016|1.5k
Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis
|Journal of Clinical Investigation|2000|1.3k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k